Although analysts appear reserved in their sentiment, insiders appear quite positive in regard to the future of ZymoGenetics Inc. (NASDAQ: ZGEN). However, short interest in the company has been increasing and is running at approximately 18% of float. The company is currently engaged in marketing it's protein based treatment for stopping blood loss during surgery. It faces entrenched competition in that field.

I myself would have no desire to short this stock right now, even though its level of return stinks to high heaven. The major impetus behind why I think short sellers are in essence shorting themselves is multifaceted. First, ZymoGenetics reported 2007 increases in sales and gross profits, even as the company made clear that it is years from profitability. Second, as reported by Forbes, New York-based private equity firm, Warburg Pincus has increased its stake in ZymoGenetics and is considering a request for greater presence on the board. Third, and finally, I simply think that ZymoGenetics shares are at their natural bottom. To me, the indications I get from the company's share movements of late have all the earmarks of a classic Wall Street tug of war.

I'd be tempted to jump in on this stock right now myself, but only with long term intent and only with a gambler's share. Press clips give me the impression that the company's team knows what it's doing on the pharmaceutical side. The basic financial numbers, however, indicate to me that the company needs some modest cleaning up in that regard.

ZymoGenetics stock is currently trading within the very bottom of its previous five year range. Analysts are positive but quietly reserved on this stock. Analyst consensus is a firm hold.

Gary Sattler is a freelance blogger with no stock picking credentials. He does not knowingly hold interest in the companies mentioned in this blog post.